KR960003728A - 포유류의 허파 모세관 누출을 감소시키는 방법 - Google Patents

포유류의 허파 모세관 누출을 감소시키는 방법 Download PDF

Info

Publication number
KR960003728A
KR960003728A KR1019950019351A KR19950019351A KR960003728A KR 960003728 A KR960003728 A KR 960003728A KR 1019950019351 A KR1019950019351 A KR 1019950019351A KR 19950019351 A KR19950019351 A KR 19950019351A KR 960003728 A KR960003728 A KR 960003728A
Authority
KR
South Korea
Prior art keywords
methotrexate
interleukin
administration
administered
lung capillary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019950019351A
Other languages
English (en)
Korean (ko)
Inventor
에스 커워 슈레쉬
엠 위크 마이클
Original Assignee
윌리엄 에이취 캘넌
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리엄 에이취 캘넌, 아메리칸 사이아나밋드 캄파니 filed Critical 윌리엄 에이취 캘넌
Publication of KR960003728A publication Critical patent/KR960003728A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019950019351A 1994-07-01 1995-06-30 포유류의 허파 모세관 누출을 감소시키는 방법 Withdrawn KR960003728A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/269702 1994-07-01
US08/269,702 US5593671A (en) 1994-07-01 1994-07-01 Method of attenuating lung capillary leak in a mammal

Publications (1)

Publication Number Publication Date
KR960003728A true KR960003728A (ko) 1996-02-23

Family

ID=23028336

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950019351A Withdrawn KR960003728A (ko) 1994-07-01 1995-06-30 포유류의 허파 모세관 누출을 감소시키는 방법

Country Status (9)

Country Link
US (1) US5593671A (enExample)
EP (1) EP0692251A1 (enExample)
JP (1) JPH0826998A (enExample)
KR (1) KR960003728A (enExample)
AU (1) AU2335195A (enExample)
CA (1) CA2152981A1 (enExample)
HU (1) HUT74245A (enExample)
NZ (1) NZ272476A (enExample)
TW (1) TW294596B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115397B1 (en) 1998-08-28 2006-05-24 Intarcia Therapeutics, Inc. Compositions for mitigating the adverse effects of interleukin-2
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU2001283191A1 (en) * 2000-08-10 2002-02-25 Uab Research Foundation Compositions containing an inhibitor of dihydrofolate reductase and a folate
AU2005227263A1 (en) * 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf

Also Published As

Publication number Publication date
JPH0826998A (ja) 1996-01-30
TW294596B (enExample) 1997-01-01
NZ272476A (en) 1997-06-24
HU9501980D0 (en) 1995-08-28
EP0692251A1 (en) 1996-01-17
AU2335195A (en) 1996-01-18
CA2152981A1 (en) 1996-01-02
HUT74245A (en) 1996-11-28
US5593671A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
BR0211794A (pt) Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
LU91079I2 (fr) Tramacet et ses dérivés pharmaceutiquement acceptables.
KR970706815A (ko) 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)
AR012417A1 (es) COMPOSICIoN FARMACÉUTICA DE ADMINISTRACIoN ORAL Y PROCEDIMIENTO PARA SU PRODUCCION.
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
DE69733089D1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
GT200100063A (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos
KR960003728A (ko) 포유류의 허파 모세관 누출을 감소시키는 방법
FR2674754B1 (fr) Composition medicamenteuse micronisee.
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
ES2180200T3 (es) Composicion para la supresion de los sintomas de abstinencia y ansia de alcohol en alcoholicos y prevencion del abuso de alcohol en individuos sanos.
KR900701259A (ko) 다가 소염제
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
ATE134294T1 (de) Zusammensetzung mit psyllium
SE8004744L (sv) Nya tripeptidamider, som inverkar pa det centrala nervsystemet, jemte sett for deras framstellning
KR900700123A (ko) 조성물 및 포유류에서의 리포단백질 콜레스테롤 프로필의 개선을 위한 용도
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료
KR920021144A (ko) 역류성 식도염을 치료하기위한 니자티딘의 용도
PT1058544E (pt) Inibicao da actividade do tnf
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
KR910002792A (ko) 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물
BR0107630A (pt) Composição
KR910016327A (ko) 호중구에 의한 엘라스타제 방출 저해제로서의 테니댑의 용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19950630

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid